WINTON GROUP Ltd Decreases Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

WINTON GROUP Ltd lowered its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 13.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 176,685 shares of the medical instruments supplier’s stock after selling 27,582 shares during the period. WINTON GROUP Ltd’s holdings in OraSure Technologies were worth $638,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of OSUR. Raymond James Financial Inc. purchased a new position in OraSure Technologies in the fourth quarter worth about $37,000. Atom Investors LP purchased a new position in shares of OraSure Technologies in the third quarter worth approximately $49,000. AXQ Capital LP purchased a new position in shares of OraSure Technologies in the fourth quarter worth approximately $51,000. US Bancorp DE increased its holdings in OraSure Technologies by 310.4% during the fourth quarter. US Bancorp DE now owns 19,433 shares of the medical instruments supplier’s stock valued at $70,000 after buying an additional 14,698 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in OraSure Technologies in the third quarter worth approximately $84,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Insider Buying and Selling

In related news, CFO Kenneth J. Mcgrath bought 64,000 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average price of $3.15 per share, for a total transaction of $201,600.00. Following the completion of the transaction, the chief financial officer now owns 371,013 shares in the company, valued at $1,168,690.95. The trade was a 20.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director John P. Kenny bought 47,659 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average cost of $3.17 per share, with a total value of $151,079.03. Following the completion of the purchase, the director now directly owns 70,915 shares of the company’s stock, valued at $224,800.55. This represents a 204.93 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 190,284 shares of company stock worth $600,348. 3.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th.

OraSure Technologies Stock Performance

Shares of OSUR stock opened at $3.43 on Friday. The stock has a fifty day simple moving average of $3.69 and a two-hundred day simple moving average of $3.88. The firm has a market capitalization of $256.56 million, a PE ratio of 22.87 and a beta of -0.02. OraSure Technologies, Inc. has a 52-week low of $2.69 and a 52-week high of $6.35.

OraSure Technologies announced that its board has approved a share repurchase program on Monday, March 24th that permits the company to repurchase $40.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 15.6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.